EYPT · EyePoint Pharmaceuticals, Inc.

Summary

EyePoint Pharmaceuticals, Inc. announced Q4 and full-year 2025 financial results with total net revenue of $0.6 million and $31.4 million, respectively, and net losses of $67.6 million and $232.0 million. The company reported $306 million in cash providing runway into Q4 2027, Phase 3 trial progress for DURAVYU in wet AMD and DME, and appointed Michael Campbell as Chief Commercial Officer.

Key takeaways

• Event Type: Earnings Release and Executive Appointment (Items: 2.02, 5.02)